Topline data for Lumakras Phase III CodeBreaK 200 trial in NSCLC
Amgen announced that the global Phase III CodeBreaK 200 trial evaluating once daily oral Lumakras (sotorasib) met its primary endpoint of progression-free survival (PFS), demonstrating statistical significance and superiority over standard of care chemotherapy, intravenous docetaxel
The first randomized clinical trial for a KRASG12C inhibitor assessed the efficacy and safety of Lumakras in 345 previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) who had received at minimum, prior platinum-based doublet chemotherapy and checkpoint inhibitor therapy.
150 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.